Spinello Angelo, Bonsignore Riccardo, Barone Giampaolo, Keppler Bernhard K, Terenzi Alessio
Institute of Inorganic Chemistry, University of Vienna, Waehringerstr. 42, A-1090 Vienna, Austria.
Curr Pharm Des. 2016;22(26):3996-4010. doi: 10.2174/1381612822666160520115248.
Alzheimer's disease (AD) is the most common form of dementia that seriously affects daily life. Even if AD pathogenesis is still subject of debate, it is generally accepted that cerebral cortex plaques formed by aggregated amyloid-β (Aβ) peptides can be considered a characteristic pathological hallmark. It is well known that metal ions play an important role in the aggregation process of Aβ.
This review focuses on the anti-Aβ aggregation activity of chelating ligands as well as on the use of metal complexes as diagnostic probes and as potential drugs.
While chelating agents, such as curcumin or flavonoid derivatives, are currently used to capture metal ions responsible for Aβ aggregation, the potential application of platinum, ruthenium and cobalt complexes, among others, of several heterocyclic ligands, represents a promising new strategy to fight AD.
阿尔茨海默病(AD)是最常见的痴呆形式,严重影响日常生活。尽管AD的发病机制仍存在争议,但普遍认为由聚集的淀粉样β(Aβ)肽形成的大脑皮质斑块可被视为特征性病理标志。众所周知,金属离子在Aβ的聚集过程中起重要作用。
本综述重点关注螯合配体的抗Aβ聚集活性,以及金属配合物作为诊断探针和潜在药物的应用。
虽然目前使用姜黄素或类黄酮衍生物等螯合剂来捕获导致Aβ聚集的金属离子,但几种杂环配体的铂、钌和钴配合物等的潜在应用代表了对抗AD的一种有前景的新策略。